Dublin, Sept. 18, 2023 (GLOBE NEWSWIRE) -- The "Obsessive-Compulsive Disorder - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
Obsessive-Compulsive Disorder (OCD) is a mental health condition that has gained increasing recognition in recent years. A report titled "Obsessive Compulsive Disorder (OCD) - Market Insights, Epidemiology and Market Forecast - 2032" provides a thorough examination of OCD, offering historical and projected epidemiological data as well as insights into market trends across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
Understanding OCD Epidemiology
The report delves into OCD's epidemiology, segmenting data by total prevalent cases, diagnosed cases, gender-specific cases, severity-specific cases, and age-specific cases. In the seven major markets (7MM), including the United States, EU4 countries, the United Kingdom, and Japan, the prevalence of OCD is projected to increase significantly from 2019 to 2032. For instance, the total prevalent cases of OCD in the 7MM reached around 12,082,000 cases in 2022, with further growth anticipated.
The United States accounts for a substantial portion of OCD cases in the 7MM, contributing approximately 29% to the prevalent population. Meanwhile, EU4 and the UK, along with Japan, hold shares of approximately 53% and 18%, respectively. Germany leads among the EU4 and the UK in terms of OCD cases, followed by France, while the United Kingdom reports the lowest number of prevalent cases. In 2022, Japan recorded approximately 1,099,000 diagnosed cases of OCD.
Exploring OCD Drug Landscape
The report offers a detailed analysis of OCD-marketed drugs and late-stage pipeline drugs. It delves into clinical trial details, pharmacological action, agreements, collaborations, approval and patent information, and the advantages and disadvantages of each drug.
Marketed Drugs: ZOLOFT (sertraline hydrochloride)
ZOLOFT, developed by Biohaven Pharmaceuticals, is a notable drug for OCD treatment. Sertraline hydrochloride, the active ingredient, acts as a selective serotonin-reuptake inhibitor (SSRI), which is administered orally to treat not only OCD but also conditions like depression, panic disorder, and post-traumatic stress disorder. Sertraline hydrochloride has demonstrated its efficacy in raising serotonin levels in the central nervous system by inhibiting neuronal reuptake of serotonin.
Emerging Drug: Troriluzole
Troriluzole, another promising candidate developed by Biohaven Pharmaceuticals, is currently in the late-stage pipeline. It is a tripeptide prodrug of the active metabolite riluzole, designed for enhanced bioavailability, pharmacokinetics, tolerability, and dosing. Clinical trials have demonstrated troriluzole's potential therapeutic benefits in neurological and neuropsychiatric illnesses, including OCD.
The Phase II/III study of troriluzole showed promising preliminary results, indicating its effectiveness and tolerability. This could position troriluzole as a leading treatment for OCD patients, pending Phase III study results and FDA approval.
Outlook for OCD Market
Effective treatment options for OCD primarily encompass Cognitive Behavior Therapy (CBT) and medication. CBT, specifically Exposure and Response Prevention (ERP), and Selective Serotonin Reuptake Inhibitors (SSRIs) are considered first-line treatments. While these treatments are effective for many patients, approximately 40-60% do not respond adequately to them, highlighting unmet medical needs.
However, growing awareness of OCD's symptoms, diagnosis, causes, and treatments worldwide has led to the exploration of novel therapeutic pathways. One such potential therapy is Biohaven Pharmaceuticals' troriluzole, which shows promise in clinical trials.
OCD Drugs Uptake and Pipeline Development
The report assesses the uptake rate of potential drugs expected to enter the market between 2019 and 2032. Troriluzole, for instance, is projected to witness slow-medium uptake, with a probability-adjusted peak share of approximately 4% within eight years from its launch.
Pipeline Development Activities and KOL Views
The report provides insights into the therapeutic candidates in various phases of development, including Phase III, Phase II, and Phase I. It also explores key players involved in targeted therapeutics.
Furthermore, the report draws on the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) in the field of OCD. These experts offer insights into the evolving treatment landscape, patient reliance on existing therapies, therapy switching acceptability, and drug uptake. Their valuable input validates research findings and contributes to a comprehensive understanding of the OCD market.
Market Access and Reimbursement
The report offers detailed insights into accessibility and reimbursement scenarios in different countries. It covers the cost-effectiveness of approved therapies, programs that enhance accessibility and affordability, and the status of patients insured under government prescription drug programs.
In conclusion, OCD, once a neglected illness, is now recognized as a common and treatable early-onset brain disorder. Clinical and translational research in OCD has advanced significantly, leading to innovations in diagnostics, therapeutic interventions, and services. The future of OCD treatment appears promising, with potential therapies in the pipeline. However, challenges such as treatment resistance and side effects will determine the impact of these therapies on revenue generation and overall patient well-being. As the understanding of disease etiology grows, more therapeutic targets are likely to emerge, driving the development of novel OCD treatments in the coming years.
For more information about this report visit https://www.researchandmarkets.com/r/v1h6sa
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
